$APTO Focuses on Aptose Biosciences, Inc. is a
Post# of 29735
Aptose Biosciences, Inc. is a clinical-stage oncology company, which focuses on the discovery, research and development of anticancer therapies. Its product portfolio includes APTO-253, a small molecule that induce expression of the Kruppel-Like Factor 4 (KLF4) genes; and CG'806. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.